Emergent BioSolutions Inc (EBS) Stock
Key stats
- Market cap
- $310.55M
- Price / Earnings ratio
- -1.2x
- EPS (TTM)
- -$5.01
- Volume
- Loading
- 52-week high
- $14.06
- 52-week low
- $4.36
Source: third-party data provider, as of November 13, 2026
Compare with EBS
Recent news

Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
EBS

Emergent Biosolutions Q3 Earnings Call Highlights
Emergent Biosolutions Q3 Earnings Call Highlights
EBS

Emergent Biosolutions Reports Third Quarter 2026 Financial Results
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
EBS

Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
EBS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 42.51
- MACD 12/26/9
- -0.15
- EMA 9 of MACD
- -0.09
- MACD histogram
- -0.06
- SMA 50
- $6.52
- Price below SMA 50
- EMA 50
- $6.48
- Price below EMA 50
- SMA 200
- $7.79
- Price below SMA 200
- EMA 200
- $8.08
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Sell
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market has no earnings per share expectations for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
EBS

Emergent Biosolutions Q3 Earnings Call Highlights
Emergent Biosolutions Q3 Earnings Call Highlights
EBS

Emergent Biosolutions Reports Third Quarter 2026 Financial Results
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
EBS

Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl
EBS

Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026
EBS

Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
Emergent Biosolutions (EBS) Soars 14.4%: Is Further Upside Left in the Stock?
EBS

NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'
NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'
EBS

Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
Emergent BioSolutions Inc. (EBS) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
EBS

Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
EBS

EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
EBS Investors Have Opportunity to Join Emergent BioSolutions Inc. Fraud Investigation with SBS Law
EBS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Emergent BioSolutions Inc
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joseph C. Papa Jr., M.B.A., R.Ph. | CEO, President & Director | 1956 |
| Ms. Coleen Glessner | Executive Vice President of Quality, Ethics & Compliance | 1971 |
| Mr. Paul A. Williams | Senior Vice President of Products Business | 1967 |
| Ms. Jessica Perl | Senior VP, Corporate Secretary & General Counsel | 1981 |
| Assal Hellmer | Vice President of Communications | — |
| Ms. Michelle Pepin | Senior VP & Chief Human Resource Officer | — |
| Ms. Stephanie Duatschek | Executive VP & Chief Growth Officer | — |
| Mr. William Hartzel | Senior Vice President of Manufacturing & Bioservices | 1978 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 42.51
- MACD 12/26/9
- -0.15
- EMA 9 of MACD
- -0.09
- MACD histogram
- -0.06
- SMA 50
- $6.52
- Price below SMA 50
- EMA 50
- $6.48
- Price below EMA 50
- SMA 200
- $7.79
- Price below SMA 200
- EMA 200
- $8.08
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $10.00
- Average
- $10.00
- High
- $10.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +16.4 | -0.4 | ||||||||||
| 2022 | -2.4 | -12.0 | -1.1 | -25.8 | -2.4 | -3.5 | +8.8 | -29.8 | -11.4 | -1.0 | -41.2 | +0.0 |
| 2023 | +9.7 | -9.3 | -14.1 | -9.8 | -3.8 | -10.4 | -9.1 | -40.7 | -33.1 | -33.9 | +9.2 | +0.4 |
| 2024 | -35.5 | +95.8 | -25.4 | -18.3 | +195.3 | +11.6 | +80.0 | -21.4 | +13.0 | +7.0 | +11.0 | -2.8 |
| 2025 | +9.5 | -28.7 | -28.8 | +12.7 | +28.5 | +1.3 | -10.9 | +47.4 | +7.4 | +35.8 | +6.5 | +14.6 |
| 2026 | -9.4 | -30.4 | -7.7 | -1.8 | +7.7 | -1.3 | -12.8 | -17.7 | +6.1 | +6.9 | -6.2 |



